No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
ScinoPharm Taiwan, Ltd., along with its subsidiaries, specializes in the research, development, production, and global distribution of cGMP-compliant active pharmaceutical ingredients (APIs). The company supplies these APIs to pharmaceutical clients throughout Taiwan, the United States, Europe, India, various parts of Asia, and other international regions. Its service offerings include custom synthesis for biochemical molecules like peptides and nucleic acids, manufacturing of generic APIs, and comprehensive outsourcing solutions. ScinoPharm also provides Contract Research and Manufacturing (CRAM) services, which involve chemistry expertise, analytical and regulatory support, chemical process development, clinical drug substance manufacturing, and consulting. These CRAM services facilitate the creation and production of APIs and intermediates for clinical, small-scale, and commercial applications. Moreover, the company actively develops advanced peptide synthesis technologies. ScinoPharm is involved in the development and manufacturing of a diverse range of products, such as Western medicines, various chemical materials, albumin-based drugs, oligonucleotide medicines, injectables, and novel small molecule drugs, alongside offering biotechnology and technical services. The company holds a strategic alliance with Baxter International Inc. focused on the joint development, production, and commercialization of an antiemetic drug for cancer chemotherapy. ScinoPharm Taiwan, Ltd. was founded in 1997 and has its headquarters in Tainan City, Taiwan.
www.scinopharm.com/twNo one on the platform currently holds 1789.TW.
No tracked institution reports a position in 1789.TW as of their last filing.
No one on the platform has traded 1789.TW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 1.2% | 3.4% | 4.5% | — | — | — |
| Rev. Growth % | -7.1% | 0.5% | ||||
| Profit Margin % | 4.3% | 8.6% | 10.0% | |||
| Free Cash Flow Margin % | 9.7% | 8.9% | 17.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.8B | +18.7% | $0.46 | $0.46–$0.46 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $0.06 | $-0.04 | -168.2% |
| 2026-03-04 | $0.13 | $0.05 | -62.3% |
| 2025-11-03 | $0.10 | $0.10 | +0.0% |
| 2025-08-06 | $0.10 | $0.04 | -60.0% |
| 2025-05-07 | $0.04 | $0.04 | +0.0% |
| 2025-02-26 | $0.03 | $0.03 | +0.0% |
| 2024-11-05 | $0.08 | $0.04 | -50.0% |
| +0.14% |
| $13.5B |
| — |
| 4114.TWOSynmosa Biopharma Corporation | $29.45 | +0.34% | $15.9B | — |
| 4129.TWOUnited Orthopedic Corporation | $82.80 | +0.24% | $8.0B | — |
Source: Financial Modeling Prep · peers by sector/industry